|
Guilin Sanjin Pharmaceutical Co., Ltd. (002275.sz) Valoración de DCF
CN | Healthcare | Biotechnology | SHZ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Guilin Sanjin Pharmaceutical Co., Ltd. (002275.SZ) Bundle
Diseñada para la precisión, nuestra calculadora DCF (002275SZ) le permite evaluar Guilin Sanjin Pharmaceutical Co., Ltd. Valoración utilizando datos financieros del mundo real, al tiempo que ofrece una flexibilidad completa para modificar todos los parámetros esenciales para las medidas mejoradas.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,640.4 | 1,566.5 | 1,741.2 | 1,959.7 | 2,171.6 | 2,334.5 | 2,509.7 | 2,697.9 | 2,900.3 | 3,117.9 |
| Revenue Growth, % | 0 | -4.51 | 11.15 | 12.55 | 10.81 | 7.5 | 7.5 | 7.5 | 7.5 | 7.5 |
| EBITDA | 564.0 | 443.2 | 561.0 | 590.8 | 660.8 | 725.9 | 780.4 | 838.9 | 901.9 | 969.5 |
| EBITDA, % | 34.38 | 28.3 | 32.22 | 30.15 | 30.43 | 31.1 | 31.1 | 31.1 | 31.1 | 31.1 |
| Depreciation | 92.5 | 82.4 | 113.0 | 124.0 | 124.7 | 137.6 | 147.9 | 159.0 | 170.9 | 183.7 |
| Depreciation, % | 5.64 | 5.26 | 6.49 | 6.33 | 5.74 | 5.89 | 5.89 | 5.89 | 5.89 | 5.89 |
| EBIT | 471.5 | 360.9 | 448.0 | 466.8 | 536.1 | 588.4 | 632.5 | 679.9 | 731.0 | 785.8 |
| EBIT, % | 28.74 | 23.04 | 25.73 | 23.82 | 24.69 | 25.2 | 25.2 | 25.2 | 25.2 | 25.2 |
| Total Cash | 1,236.1 | 1,717.2 | 1,699.4 | 1,426.9 | 1,362.8 | 1,907.4 | 2,050.5 | 2,204.3 | 2,369.7 | 2,547.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 540.4 | 367.4 | 413.0 | 542.5 | 481.2 | 606.8 | 652.3 | 701.2 | 753.9 | 810.4 |
| Account Receivables, % | 32.94 | 23.45 | 23.72 | 27.68 | 22.16 | 25.99 | 25.99 | 25.99 | 25.99 | 25.99 |
| Inventories | 176.3 | 194.4 | 284.2 | 244.9 | 256.0 | 297.7 | 320.0 | 344.0 | 369.8 | 397.6 |
| Inventories, % | 10.75 | 12.41 | 16.32 | 12.5 | 11.79 | 12.75 | 12.75 | 12.75 | 12.75 | 12.75 |
| Accounts Payable | 125.2 | 91.6 | 180.2 | 133.9 | 201.4 | 186.5 | 200.4 | 215.5 | 231.6 | 249.0 |
| Accounts Payable, % | 7.63 | 5.84 | 10.35 | 6.83 | 9.27 | 7.99 | 7.99 | 7.99 | 7.99 | 7.99 |
| Capital Expenditure | -226.1 | -205.5 | -144.1 | -62.3 | -76.4 | -195.5 | -210.2 | -225.9 | -242.9 | -261.1 |
| Capital Expenditure, % | -13.79 | -13.12 | -8.28 | -3.18 | -3.52 | -8.37 | -8.37 | -8.37 | -8.37 | -8.37 |
| Tax Rate, % | 18.71 | 18.71 | 18.71 | 18.71 | 18.71 | 18.71 | 18.71 | 18.71 | 18.71 | 18.71 |
| EBITAT | 395.4 | 290.5 | 358.9 | 344.7 | 435.8 | 470.2 | 505.5 | 543.4 | 584.2 | 628.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -329.8 | 288.7 | 281.1 | 270.0 | 601.8 | 230.1 | 389.3 | 418.5 | 449.9 | 483.7 |
| WACC, % | 6.31 | 6.31 | 6.3 | 6.29 | 6.31 | 6.3 | 6.3 | 6.3 | 6.3 | 6.3 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,618.0 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 501 | |||||||||
| Terminal Value | 17,852 | |||||||||
| Present Terminal Value | 13,150 | |||||||||
| Enterprise Value | 14,768 | |||||||||
| Net Debt | -530 | |||||||||
| Equity Value | 15,298 | |||||||||
| Diluted Shares Outstanding, MM | 585 | |||||||||
| Equity Value Per Share | 26.14 |
What You Will Receive
- Authentic Guilin Sanjin Data: Comprehensive financials – covering revenue to EBIT – based on real and projected metrics.
- Complete Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- Immediate Valuation Reflections: Automatic recalculations to assess the influence of changes on the fair value of Guilin Sanjin Pharmaceutical (002275SZ).
- Flexible Excel Template: Designed for easy edits, scenario analysis, and in-depth projections.
- Efficient and Accurate: Avoid the hassle of building models from scratch while ensuring precision and adaptability.
Key Features
- Comprehensive AAPL Data: Pre-populated with Guilin Sanjin Pharmaceutical's historical financial information and future projections.
- Customizable Inputs: Modify revenue growth rates, profit margins, WACC, tax rates, and capital expenditures to suit your analysis.
- Dynamic Valuation Model: Automatically recalculates Net Present Value (NPV) and intrinsic value based on your adjusted parameters.
- Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation results.
- User-Friendly Interface: Intuitive and organized design catering to both professionals and novices.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Guilin Sanjin Pharmaceutical's pre-filled financial data and forecasts.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the findings for your investment strategies.
Why Choose This Calculator for Guilin Sanjin Pharmaceutical Co., Ltd. (002275SZ)?
- Reliable Data: Utilize genuine financials of Guilin Sanjin for trustworthy valuation outcomes.
- Tailored Options: Customize essential variables like growth rates, WACC, and tax rates to align with your forecasts.
- Efficient: Built-in calculations save you the hassle of starting from the ground up.
- Professional Quality: Ideal for investors, analysts, and consultants in the pharmaceutical sector.
- Easy to Use: User-friendly design and clear, step-by-step guidance ensure accessibility for all users.
Who Should Utilize This Product?
- Individual Investors: Make well-informed decisions regarding the purchase or sale of Guilin Sanjin Pharmaceutical Co., Ltd. (002275SZ) stock.
- Financial Analysts: Enhance valuation processes with readily accessible financial models tailored for Guilin Sanjin Pharmaceutical Co., Ltd. (002275SZ).
- Consultants: Provide clients with prompt and precise valuation insights related to Guilin Sanjin Pharmaceutical Co., Ltd. (002275SZ).
- Business Owners: Gain a better understanding of how pharmaceutical companies like Guilin Sanjin Pharmaceutical Co., Ltd. (002275SZ) are valued to refine your strategic approach.
- Finance Students: Explore valuation techniques through the lens of real-world data and examples involving Guilin Sanjin Pharmaceutical Co., Ltd. (002275SZ).
Contents of the Template
- Pre-Filled Data: Contains Guilin Sanjin Pharmaceutical’s historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic computation features.
- Weighted Average Cost of Capital (WACC): A dedicated worksheet to compute WACC based on user-defined inputs.
- Key Financial Ratios: Evaluate Guilin Sanjin Pharmaceutical’s profitability, efficiency, and financial leverage.
- Customizable Inputs: Easily adjust revenue growth rates, profit margins, and tax rates.
- Clear Dashboard: Visual representations with charts and tables summarizing essential valuation metrics.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.